What is the onset time and clinical duration of action after intravenous administration of rocuronium 2 mg per kilogram?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rocuronium 2 mg/kg: Onset and Duration

At a dose of 2 mg/kg, rocuronium is not a standard dosing regimen and lacks specific pharmacodynamic data in the provided evidence. However, based on the dose-response relationship established in FDA labeling and clinical studies, this supramaximal dose (approximately 6-7 times the ED95) would be expected to produce an extremely rapid onset of less than 1 minute and a prolonged clinical duration exceeding 60-90 minutes.

Understanding the Dose-Response Relationship

The FDA-approved rocuronium labeling provides clear pharmacodynamic parameters for standard doses 1:

Standard Dosing Parameters:

  • 0.6 mg/kg (2 × ED95): Onset to 80% block in median 1.0 minute (range 0.4-6 minutes), with maximum blockade in less than 3 minutes and clinical duration of 31 minutes (15-85 minutes) 1
  • 0.9-1.2 mg/kg (3-4 × ED95): Can be administered safely without adverse cardiovascular effects 1

Extrapolating to 2 mg/kg

While 2 mg/kg is not specifically studied in the provided evidence, the dose-response curves demonstrate:

Expected Onset:

  • Onset time decreases logarithmically with increasing dose
  • At 1.2 mg/kg, onset approaches that of succinylcholine
  • At 2 mg/kg, onset would likely be 30-60 seconds to maximum blockade

Expected Duration:

  • Clinical duration increases linearly with dose
  • The 1.2 mg/kg dose referenced in guidelines for "very deep blockade" requiring 8 mg/kg sugammadex for immediate reversal 2
  • At 2 mg/kg, clinical duration (to 25% recovery) would likely exceed 60-90 minutes

Clinical Context and Reversal Implications

This supramaximal dose creates a "very deep blockade" scenario. According to 2020 French guidelines on muscle relaxants 2:

Reversal Requirements:

  • Very deep blockade (3-15 minutes after high doses of 1.0-1.2 mg/kg) requires sugammadex 8 mg/kg for reversal in 3-5 minutes
  • At 2 mg/kg rocuronium, you would need sugammadex 8 mg/kg for immediate reversal
  • Neostigmine would be completely ineffective until substantial spontaneous recovery occurs

Important Caveats

Why This Dose Is Not Standard:

  • No clinical indication for such high dosing in routine practice
  • Prolonged paralysis without proportional clinical benefit
  • Increased risk of residual paralysis
  • Significantly increased cost (both drug and reversal agent)
  • Recent evidence suggests doses >1.2 mg/kg improve first-attempt intubation success 3, 4, but 2 mg/kg exceeds even these recommendations

Patient-Specific Factors:

  • Elderly patients and those with renal/hepatic impairment would have even more prolonged effects 2
  • Females demonstrate greater sensitivity to rocuronium 5
  • Sickle cell patients show paradoxically longer onset and shorter duration 6

Monitoring is Essential:

  • Quantitative neuromuscular monitoring (TOF) is mandatory at any dose
  • Post-tetanic count (PTC) monitoring needed for very deep blockade
  • Continued monitoring after reversal to detect recurarization 2

References

Guideline

guidelines on muscle relaxants and reversal in anaesthesia.

Anaesthesia Critical Care & Pain Medicine, 2020

Research

Influence of age and gender on the pharmacodynamic parameters of rocuronium during total intravenous anesthesia.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2011

Research

Pharmacodynamics of rocuronium in sickle cell patients.

Anaesthesia, critical care & pain medicine, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.